Studies have shown that IL-17 may have a beneficial effect on tumor growth and disease progression, while some preclinical research efforts indicate that IFN-γ-dependent IL-17 production by T cells can lead to elimination of tumors in vivo and establish tumor-specific immune responses [39, 40]. This evidence concerns the gene IL17A and neoplasm.